Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group (Q54258362)
scientific article published on November 1, 1992
Language:
Current Data About Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group
(P31) (Q13442814)
(P248)
(P698) 1486035
(P813) Saturday, May 26, 2018
(P854) http://europepmc.org/abstract/MED/1486035

(P304) 555-559
(P248)
(P698) 1486035
(P813) Saturday, May 26, 2018
(P854) http://europepmc.org/abstract/MED/1486035

(P407) (Q1860)

(P433) 3
(P248)
(P698) 1486035
(P813) Saturday, May 26, 2018
(P854) http://europepmc.org/abstract/MED/1486035

(P478) 82
(P248)
(P698) 1486035
(P813) Saturday, May 26, 2018
(P854) http://europepmc.org/abstract/MED/1486035

(P577) Sunday, November 1, 1992
(P248)
(P698) 1486035
(P813) Saturday, May 26, 2018
(P854) http://europepmc.org/abstract/MED/1486035

(P921) (Q16)

(Q422252)
(P887)

(P1433) (Q4970200)
(P248)
(P698) 1486035
(P813) Saturday, May 26, 2018
(P854) http://europepmc.org/abstract/MED/1486035

(P1476) "Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group" (language: en)
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

(P2093) G. P. Browman
(P1545) 1
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

A. Belch
(P1545) 2
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

J. Skillings
(P1545) 3
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

K. Wilson
(P1545) 4
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

D. Bergsagel
(P1545) 5
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

D. Johnston
(P1545) 6
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

J. L. Pater
(P1545) 7
(P248)
(P698) 1486035
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1486035
(P813) Saturday, October 1, 2022

(P2860) (Q41924796)
(P248)
(P854) https://api.crossref.org/works/10.1111%2FJ.1365-2141.1992.TB06466.X
(P813) Sunday, January 21, 2018

(Q44368521)
(P248)
(P854) https://api.crossref.org/works/10.1111%2FJ.1365-2141.1992.TB06466.X
(P813) Sunday, January 21, 2018

other details
description scientific article published on November 1, 1992

External Links
(P356) 10.1111/J.1365-2141.1992.TB06466.X
(P698) 1486035